Cargando…

The design of a randomized, placebo-controlled, dose-ranging trial to investigate the efficacy and safety of the ADAMTS-5 inhibitor S201086/GLPG1972 in knee osteoarthritis

OBJECTIVE: This study aims to assess the efficacy of the anticatabolic ‘a disintegrin and metalloproteinase with thrombospondin motif-5’ (ADAMTS-5) inhibitor, S201086/GLPG1972, in slowing cartilage loss in participants with knee osteoarthritis (OA). DESIGN: ROCCELLA (NCT03595618) is a randomized, do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imbert, Olivier, Deckx, Henri, Bernard, Katy, van der Aar, Ellen, Pueyo, Maria, Saeed, Nadeem, Fuerst, Thomas, Wirth, Wolfgang, Conaghan, Philip G., Eckstein, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	ORIGINAL PAPER
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718074/ https://www.ncbi.nlm.nih.gov/pubmed/36474770 http://dx.doi.org/10.1016/j.ocarto.2021.100209

Ejemplares similares

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip
por: van der Aar, Ellen, et al.
Publicado: (2021)

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
por: Meyer, Claudia, et al.
Publicado: (2022)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021)

A simple inclusion criteria combination increases the rate of cartilage loss in patients with knee osteoarthritis
por: Imbert, Olivier, et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
por: van der Aar, Ellen, et al.
Publicado: (2019)

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
por: Taneja, Amit, et al.
Publicado: (2019)

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial
por: Strambu, Irina R., et al.
Publicado: (2023)

Association of Superficial Cartilage Transverse Relaxation Time With Osteoarthritis Disease Progression: Data From the Foundation for the National Institutes of Health Biomarker Study of the Osteoarthritis Initiative
por: Fuerst, David, et al.
Publicado: (2022)

Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo
por: Colapietro, Alessandro, et al.
Publicado: (2020)

The Mechanism and Role of ADAMTS Protein Family in Osteoarthritis
por: Li, Ting, et al.
Publicado: (2022)

Steric trapping reveals a cooperativity network in the intramembrane protease GlpG
por: Guo, Ruiqiong, et al.
Publicado: (2016)

Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
por: Yeh, Han-I, et al.
Publicado: (2019)

The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019)

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells
por: Megiorni, Francesca, et al.
Publicado: (2017)

The role of ADAMTS genes in the end stage of hip osteoarthritis
por: Ayanoglu, Tacettin, et al.
Publicado: (2019)

Epigenetic regulatory mechanism of ADAMTS12 expression in osteoarthritis
por: Yang, Shu, et al.
Publicado: (2023)

GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
por: Timmis, Helen, et al.
Publicado: (2021)

Genetic variation of aggrecanase-2 (ADAMTS5) in susceptibility to osteoarthritis
por: Zhou, Xindie, et al.
Publicado: (2019)

ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the ‘usual suspects’
por: Yang, C.-Y., et al.
Publicado: (2017)

The Rhomboid Protease GlpG Promotes the Persistence of Extraintestinal Pathogenic Escherichia coli within the Gut
por: Russell, Colin W., et al.
Publicado: (2017)

Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration
por: Helmer, Eric, et al.
Publicado: (2021)

Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
por: Blanqué, Roland, et al.
Publicado: (2014)

Quantitative Cartilage Imaging in Knee Osteoarthritis
por: Eckstein, Felix, et al.
Publicado: (2011)

VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts
por: Pérez‐García, Selene, et al.
Publicado: (2016)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

The utility of synovial fluid levels of ADAMTS9 and ADAMTS4 in predicting treatment responses to intraarticular steroid injections in patients with knee osteoarthritis
por: ÖZLER, Kenan
Publicado: (2020)

Accuracy and longitudinal reproducibility of quantitative femorotibial cartilage measures derived from automated U-Net-based segmentation of two different MRI contrasts: data from the osteoarthritis initiative healthy reference cohort
por: Wirth, Wolfgang, et al.
Publicado: (2020)

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
por: Namour, Florence, et al.
Publicado: (2016)

The rhomboid protease GlpG has weak interaction energies in its active site hydrogen bond network
por: Gaffney, Kristen A., et al.
Publicado: (2019)

Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial
por: Ronaldson, Sarah J, et al.
Publicado: (2021)

ADAMTS5 in Osteoarthritis: Biological Functions, Regulatory Network, and Potential Targeting Therapies
por: Jiang, Lejian, et al.
Publicado: (2021)

ADAMTS‐4 as a possible distinguishing indicator between osteoarthritis and haemophilic arthropathy
por: Kalebota, Natasa, et al.
Publicado: (2022)

Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
por: de Wilde, Gert, et al.
Publicado: (2019)

ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5
por: Rogerson, Fraser M., et al.
Publicado: (2019)

The ADAMTS/Fibrillin Connection: Insights into the Biological Functions of ADAMTS10 and ADAMTS17 and Their Respective Sister Proteases
por: Karoulias, Stylianos Z., et al.
Publicado: (2020)

Detection of Differences in Longitudinal Cartilage Thickness Loss Using a Deep‐Learning Automated Segmentation Algorithm: Data From the Foundation for the National Institutes of Health Biomarkers Study of the Osteoarthritis Initiative
por: Eckstein, Felix, et al.
Publicado: (2022)

Inhibition of SMAD3 effectively reduces ADAMTS-5 expression in the early stages of osteoarthritis
por: Xiang, Wei, et al.
Publicado: (2023)

Meniscus position and size in knees with versus without structural knee osteoarthritis progression: data from the osteoarthritis initiative
por: Sharma, Kalpana, et al.
Publicado: (2021)

The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases
por: Lin, Edward A, et al.
Publicado: (2009)

ADAMTS9, a member of the ADAMTS family, in Xenopus development
por: Desanlis, Ines, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g6s2kv2oq5u02pv039f7al1j5u